the US Four CR and 11 PR, signature approval by the U.S. Food and Drug Administration for the treatment of relapsed refractory CTCL. B cells and Hodgkin promising Brivanib BMS-540215 results were obtained with vorinostat study its effect on tumor B-cells, in particular obtained DLBCL. This study was made of how the Phase I trial expected since only one patient of 18 showed a completely’s Full response, w While 16 patients had progressive disease and stable disease. Vorinostat in HL showed a partial response in one patient and stable disease in nine of 25 patients tested f Rderf compatibility available. A phase I-II study in non-Hodgkin’s lymphoma, with a schedule of 200 mg twice t Possible administered for 14 days on a 21-day cycle, in four patients showed CR, two PR and SD in four of the 17 patients in the study.
Panobinostat was Hodgkin’s lymphomas in a multicenter Phase II study of CT IA partial response shows in 5 treated 13 patients for a metabolic response and F 2 fluoride positron emission tomography scan D-glucose deoxy investigated in 7 12 evaluable patients. Mocetinostat was also tested in the B-cell lymphomas and SRT1720 HL. In the first case, a clinical phase II study in patients with refractory showed Rer relapsed DLBCL and follicular Ren lymphoma treated with rituximab-based regimen one CR and three PR and 13 SD DLBCL group, one patient in ten FL achieved a PR. Interestingly, patients presented with DLBCL SD PFS 6 months to 1 year. Very encouraging results have been shown in a clinical study of the II phase relapse refractory HL at a dose of 85 or 110 mg three times per week.
In the 110-mg cohort had two CR and six PR, with a very long PFS, all patients in the 85 mg cohort, a reduction of the tumor with a PR and a standard deviation. After all, SD was in 7 of 13 evaluable patients in a Phase II trial with Givinostat in HL without severe toxicity Reported t. HDACIs in the treatment of acute leukemia Mie Myelo s Myelodysplastic syndromes and the activity of t Against Leuk Mie were in pr Clinical studies paved the way for a show is large number of clinical trials in leukemia Chemistry and myelodysplastic syndromes. Clinical trials of monotherapy proved to be interesting, but limited results, perhaps due to the fact that enrolled the Phase I and II clinical relapse refractory, heavily pretreated patients. The first in the treatment of AML HDACi and high risk MDS Valproins ure Used As a well-known drug used in the treatment of epilepsy.
The most groundbreaking studies reported the clinical efficacy of VPA alone, but always h More frequently in combination with S Retino acid Each trans. A pilot study of the combination of ATRA VPA in patients aged 11 de novo AML were performed, showed a complete remission marrow in three patients, including one complete response and two other h Hematological improvement. A German study, studying the combination of ATRA, VPA was also performed in 26 patients with poor risk AML, one patient with